As of Mar 24
| +1.81 / +1.41%|
The 20 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 164.50, with a high estimate of 206.00 and a low estimate of 139.00. The median estimate represents a +26.35% increase from the last price of 130.19.
The current consensus among 21 polled investment analysts is to Buy stock in Sarepta Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.